STOCK TITAN

[SCHEDULE 13G/A] Myomo Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gil Aharon report shared beneficial ownership of 7,359,046 securities of Myomo, Inc., representing approximately 9.9% of the company’s outstanding common stock based on 37,801,070 shares reported by the issuer. The reported total comprises 3,595,788 shares of common stock and 3,763,258 shares issuable upon exercise of pre-funded warrants.

The filing states the pre-funded warrants include a blocker provision that prevents exercise to the extent it would push beneficial ownership above 9.99%, so the actual number of shares beneficially owned after giving effect to blockers is lower. Each reporting person discloses no sole voting or dispositive power and shared voting and dispositive power over the 3,595,788 common shares. The reporting persons certify the securities were acquired in the ordinary course and not to influence control of the issuer.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon e Gil Aharon comunicano la titolarità beneficiaria congiunta di 7,359,046 titoli di Myomo, Inc., corrispondenti a circa 9.9% del capitale sociale ordinario in circolazione sulla base di 37,801,070 azioni riportate dall'emittente. Il totale dichiarato comprende 3,595,788 azioni ordinarie e 3,763,258 azioni emettibili mediante l'esercizio di warrant prepagati.

La comunicazione precisa che i warrant prepagati includono una blocker provision che ne impedisce l'esercizio nella misura in cui porterebbe la partecipazione beneficiaria oltre il 9.99%, pertanto il numero effettivo di azioni detenute in via beneficiaria dopo l'applicazione dei blocker è inferiore. Ciascun dichiarante indica di non avere potere di voto o di disposizione esclusivo e di detenere congiuntamente il potere di voto e di disposizione sulle 3,595,788 azioni ordinarie. I soggetti dichiaranti attestano che i titoli sono stati acquisiti nell'ordinario corso degli affari e non con l'intento di influenzare il controllo dell'emittente.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon y Gil Aharon informan la titularidad beneficiaria compartida de 7,359,046 valores de Myomo, Inc., que representan aproximadamente el 9.9% del capital social ordinario en circulación, sobre la base de 37,801,070 acciones reportadas por el emisor. El total notificado comprende 3,595,788 acciones ordinarias y 3,763,258 acciones susceptibles de emitirse al ejercerse warrants prepagados.

La presentación indica que los warrants prepagados incluyen una blocker provision que impide el ejercicio en la medida en que éste llevaría la participación beneficiaria por encima del 9.99%, por lo que el número real de acciones propiedad beneficiaria tras aplicar los blockers es menor. Cada declarante manifiesta no tener poder exclusivo de voto o de disposición y tener poder compartido de voto y de disposición sobre las 3,595,788 acciones ordinarias. Los declarantes certifican que los valores fueron adquiridos en el curso ordinario de los negocios y no para influir en el control del emisor.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon 및 Gil Aharon은 Myomo, Inc.의 증권 7,359,046주에 대한 공동 실질보유를 보고하며, 이는 발행인이 보고한 37,801,070주를 기준으로 회사의 보통주 유통주식의 약 9.9%에 해당합니다. 보고된 총수에는 3,595,788주의 보통주와 3,763,258주의 사전충전형(pre-funded) 워런트 행사로 인출 가능한 주식이 포함됩니다.

서류에는 사전충전형 워런트에 행사로 인해 실질보유 비율이 9.99%를 초과하게 되는 경우 행사를 제한하는 blocker provision이 포함되어 있어, blocker 적용 후 실제로 실질보유되는 주식 수는 더 적다고 명시되어 있습니다. 각 보고인은 단독 의결권 또는 처분권 없음을 공개하며, 3,595,788주 보통주에 대해 의결권 및 처분권을 공동으로 보유하고 있습니다. 보고인들은 해당 증권이 정상적인 영업과정에서 취득되었으며 발행자의 지배에 영향을 주기 위한 것이 아니라고 확인합니다.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon et Gil Aharon déclarent une propriété bénéficiaire conjointe de 7,359,046 titres de Myomo, Inc., représentant environ 9.9% des actions ordinaires en circulation, sur la base de 37,801,070 actions rapportées par l'émetteur. Le total déclaré comprend 3,595,788 actions ordinaires et 3,763,258 actions susceptibles d'être émises lors de l'exercice de warrants pré-financés (pre-funded).

Le dépôt indique que les warrants pré-financés comportent une blocker provision qui empêche l'exercice dans la mesure où celui-ci ferait dépasser la participation bénéficiaire au-delà de 9.99%, de sorte que le nombre réel d'actions détenues à titre bénéficiaire après application des blockers est inférieur. Chaque déclarant indique ne pas détenir de pouvoir de vote ou de disposition exclusif et déclare exercer conjointement le pouvoir de vote et de disposition sur les 3,595,788 actions ordinaires. Les déclarants certifient que les titres ont été acquis dans le cours normal des affaires et non dans le but d'influencer le contrôle de l'émetteur.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon und Gil Aharon melden eine gemeinsame wirtschaftliche Beteiligung an 7,359,046 Wertpapieren von Myomo, Inc., die etwa 9.9% des ausstehenden Stammkapitals des Unternehmens darstellen, basierend auf 37,801,070 vom Emittenten gemeldeten Aktien. Die gemeldete Summe umfasst 3,595,788 Stammaktien und 3,763,258 Aktien, die bei Ausübung vorab finanzierter (pre-funded) Warrants auszuüben wären.

Die Meldung führt aus, dass die pre-funded Warrants eine blocker provision enthalten, die die Ausübung insoweit verhindert, als sie die wirtschaftliche Beteiligung über 9.99% hinaus erhöhen würde; daher ist die tatsächlich wirtschaftlich gehaltene Aktienanzahl nach Berücksichtigung der Blocker geringer. Jede meldende Person gibt an, weder alleinige Stimm- noch Verfügungsgewalt zu haben und gemeinsam Stimm- und Verfügungsgewalt über die 3,595,788 Stammaktien auszuüben. Die meldenden Personen bestätigen, dass die Wertpapiere im ordentlichen Geschäftsverkehr erworben wurden und nicht mit dem Ziel, die Kontrolle über den Emittenten zu beeinflussen.

Positive
  • Full disclosure of a material ~9.9% position by Rosalind entities enhances transparency for shareholders
  • Blocker provision on pre-funded warrants limits immediate exercise above 9.99% and reduces sudden control shifts
  • Clear voting and dispositive power breakdown (0 sole power; 3,595,788 shared voting/dispositive power) clarifies influence
Negative
  • Concentration near 10% represents a sizable single-party stake that could influence perception of shareholder alignment
  • Significant warrant exposure (3,763,258 pre-funded warrants) could affect future dilution if blocker provisions change
  • Shared control structure may complicate attribution of intent despite disclaimers by the adviser and portfolio manager

Insights

TL;DR: A disclosed near-10% position with warrant exposure is material but limited by blockers; further monitoring advised.

The Schedule 13G/A shows a combined reported position of 7,359,046 securities equal to ~9.9% of the outstanding common stock, split between 3,595,788 common shares and 3,763,258 pre-funded warrants. The blocker provision explicitly restricts warrant exercise above 9.99%, which constrains any immediate dilution or voting power increase. Shared voting/dispositive power and the advisory relationships are clearly disclosed, and the filers represent passive intent. For investors, this is a material ownership disclosure but not an overt control action.

TL;DR: Transparency on ownership and blocker mechanics reduces governance risk while signaling significant shareholder concentration.

The filing provides clear allocation of voting and dispositive power and an explicit statement that the adviser and portfolio manager disclaim beneficial ownership, which helps clarify governance lines. The presence of a near-10% holder is notable for board and shareholder dynamics, yet the blocker on pre-funded warrants limits immediate escalation toward control thresholds. This disclosure improves market transparency without indicating a change in corporate control.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon e Gil Aharon comunicano la titolarità beneficiaria congiunta di 7,359,046 titoli di Myomo, Inc., corrispondenti a circa 9.9% del capitale sociale ordinario in circolazione sulla base di 37,801,070 azioni riportate dall'emittente. Il totale dichiarato comprende 3,595,788 azioni ordinarie e 3,763,258 azioni emettibili mediante l'esercizio di warrant prepagati.

La comunicazione precisa che i warrant prepagati includono una blocker provision che ne impedisce l'esercizio nella misura in cui porterebbe la partecipazione beneficiaria oltre il 9.99%, pertanto il numero effettivo di azioni detenute in via beneficiaria dopo l'applicazione dei blocker è inferiore. Ciascun dichiarante indica di non avere potere di voto o di disposizione esclusivo e di detenere congiuntamente il potere di voto e di disposizione sulle 3,595,788 azioni ordinarie. I soggetti dichiaranti attestano che i titoli sono stati acquisiti nell'ordinario corso degli affari e non con l'intento di influenzare il controllo dell'emittente.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon y Gil Aharon informan la titularidad beneficiaria compartida de 7,359,046 valores de Myomo, Inc., que representan aproximadamente el 9.9% del capital social ordinario en circulación, sobre la base de 37,801,070 acciones reportadas por el emisor. El total notificado comprende 3,595,788 acciones ordinarias y 3,763,258 acciones susceptibles de emitirse al ejercerse warrants prepagados.

La presentación indica que los warrants prepagados incluyen una blocker provision que impide el ejercicio en la medida en que éste llevaría la participación beneficiaria por encima del 9.99%, por lo que el número real de acciones propiedad beneficiaria tras aplicar los blockers es menor. Cada declarante manifiesta no tener poder exclusivo de voto o de disposición y tener poder compartido de voto y de disposición sobre las 3,595,788 acciones ordinarias. Los declarantes certifican que los valores fueron adquiridos en el curso ordinario de los negocios y no para influir en el control del emisor.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon 및 Gil Aharon은 Myomo, Inc.의 증권 7,359,046주에 대한 공동 실질보유를 보고하며, 이는 발행인이 보고한 37,801,070주를 기준으로 회사의 보통주 유통주식의 약 9.9%에 해당합니다. 보고된 총수에는 3,595,788주의 보통주와 3,763,258주의 사전충전형(pre-funded) 워런트 행사로 인출 가능한 주식이 포함됩니다.

서류에는 사전충전형 워런트에 행사로 인해 실질보유 비율이 9.99%를 초과하게 되는 경우 행사를 제한하는 blocker provision이 포함되어 있어, blocker 적용 후 실제로 실질보유되는 주식 수는 더 적다고 명시되어 있습니다. 각 보고인은 단독 의결권 또는 처분권 없음을 공개하며, 3,595,788주 보통주에 대해 의결권 및 처분권을 공동으로 보유하고 있습니다. 보고인들은 해당 증권이 정상적인 영업과정에서 취득되었으며 발행자의 지배에 영향을 주기 위한 것이 아니라고 확인합니다.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon et Gil Aharon déclarent une propriété bénéficiaire conjointe de 7,359,046 titres de Myomo, Inc., représentant environ 9.9% des actions ordinaires en circulation, sur la base de 37,801,070 actions rapportées par l'émetteur. Le total déclaré comprend 3,595,788 actions ordinaires et 3,763,258 actions susceptibles d'être émises lors de l'exercice de warrants pré-financés (pre-funded).

Le dépôt indique que les warrants pré-financés comportent une blocker provision qui empêche l'exercice dans la mesure où celui-ci ferait dépasser la participation bénéficiaire au-delà de 9.99%, de sorte que le nombre réel d'actions détenues à titre bénéficiaire après application des blockers est inférieur. Chaque déclarant indique ne pas détenir de pouvoir de vote ou de disposition exclusif et déclare exercer conjointement le pouvoir de vote et de disposition sur les 3,595,788 actions ordinaires. Les déclarants certifient que les titres ont été acquis dans le cours normal des affaires et non dans le but d'influencer le contrôle de l'émetteur.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon und Gil Aharon melden eine gemeinsame wirtschaftliche Beteiligung an 7,359,046 Wertpapieren von Myomo, Inc., die etwa 9.9% des ausstehenden Stammkapitals des Unternehmens darstellen, basierend auf 37,801,070 vom Emittenten gemeldeten Aktien. Die gemeldete Summe umfasst 3,595,788 Stammaktien und 3,763,258 Aktien, die bei Ausübung vorab finanzierter (pre-funded) Warrants auszuüben wären.

Die Meldung führt aus, dass die pre-funded Warrants eine blocker provision enthalten, die die Ausübung insoweit verhindert, als sie die wirtschaftliche Beteiligung über 9.99% hinaus erhöhen würde; daher ist die tatsächlich wirtschaftlich gehaltene Aktienanzahl nach Berücksichtigung der Blocker geringer. Jede meldende Person gibt an, weder alleinige Stimm- noch Verfügungsgewalt zu haben und gemeinsam Stimm- und Verfügungsgewalt über die 3,595,788 Stammaktien auszuüben. Die meldenden Personen bestätigen, dass die Wertpapiere im ordentlichen Geschäftsverkehr erworben wurden und nicht mit dem Ziel, die Kontrolle über den Emittenten zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 37,801,070 shares of the Issuer's common stock outstanding as of August 11th, 2025, in accordance with information provided by the issuer. However, as more fully described in Item 4, the securities reported in rows (6), (8), and (9) show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8), and (9). (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/11/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/11/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/11/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/11/2025

FAQ

What stake does Rosalind report in Myomo (MYO)?

The reporting persons disclose a combined beneficial interest of 7,359,046 securities, representing approximately 9.9% of Myomo’s common stock.

How is the 7,359,046 total composed?

It consists of 3,595,788 shares of common stock and 3,763,258 shares issuable upon exercise of pre-funded warrants.

Do the filers have sole voting or dispositive power over these shares?

No. Each reporting person reports 0 sole voting power and 3,595,788 shared voting and dispositive power over the common shares.

What is the effect of the blocker provision mentioned in the filing?

The blocker provision prevents exercise of pre-funded warrants to the extent that doing so would increase beneficial ownership above 9.99%, so the actual exercisable ownership is limited.

Did the filers state their purpose for acquiring the securities?

Yes. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.
Myomo

NYSE:MYO

MYO Rankings

MYO Latest News

MYO Latest SEC Filings

MYO Stock Data

66.56M
30.63M
6.95%
62.65%
5.21%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BOSTON